Benadryl case study
Different classes of drugs have different mechanisms of actions. That is the case given that they target to exert a more specific and unique response in the body. In essence, this discussion aims to establish the mechanism of action of Benadryl (diphenhydramine) and differentiate between histamine 1 and 2 (H1 and H2) blockers. In light of this information, it is beyond doubt that one will gain more insight on these pharmacological agents.
Primarily, Benadryl is an antihistamine mainly used to treat manifestations of allergic reaction like sneezing, itchiness, runny nose, rashes and hives. Its mechanism of action in the body is that it targets to block the binding of free histamine to H1 receptors by competing with the free histamine for these sites. The binding of the free histamines to H1 receptors is the physiological explanation for allergic reactions (Schatzberg, & Nemeroff, 2013).
Lastly, the H1 and H2 blockers have distinct differences that are worth noting. One and most obvious difference is one that relates to their mechanism of action. H1 blockers mainly prevent free histamine from binding to H1 receptors that are common in the respiratory muscles. On the contrary, H2 blockers inhibit the binding of the free histamine to the H2 receptors that are common in the stomach lumen. Another difference is that H1 blockers are mainly for allergic purposes while the H2 blockers mostly aim to reduce the secretion of peptic acid in the stomach (Lehne, 2013). Clearly, with such instances, it is beyond doubt that H1 and H2 blockers are very different classes of drugs.
In closure, this paper aimed at establishing the mechanism of action of Benadryl and differentiating between H1 and H2 blockers. Indeed, it has achieved its objective. The implication drawn from this discussion is that one must consider such information in practice to avoid instances of medical errors.
References
Lehne, R. A. (2013). Pharmacology for nursing care. St. Louis, Mo: Elsevier/Saunders.
Schatzberg, A. F., & Nemeroff, C. B. (2013). Essentials of clinical psychopharmacology. Washington, DC: American Psychiatric Pub.
